FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) is conducting joint research with Keio University School of Medicine (Location: Shinjuku-ku, Tokyo) to diagnose dementia using AI. We announce that we have agreed with Keio University School of Medicine to license the support system.

Since 2015, FRONTEO has been conducting research on the dementia diagnosis AI system in collaboration with Keio University School of Medicine, but this time, in order to promote smoother commercialization, FRONTEO has exclusively aimed at developing medical devices for this system. We have accepted the development and sales rights from Keio University School of Medicine. FRONTEO aims for early commercialization and early market penetration of this system created through industry-academia collaboration in the medical field.

About dementia diagnosis support AI system URL: https://lifescience.fronteo.com/operations/

The dementia diagnosis support AI system is FRONTEO's original natural language analysis AI "Concept Encoder (registered trademark: concept encoder).^®, Reading: Concept Encoder) ”is a system that can screen for cognitive dysfunction from daily conversation between a patient and a doctor for about 5 to 10 minutes.We believe that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which is facing a super-aging society. .. FRONTEO entered into a business alliance agreement with Kyowa Pharmaceutical Industry Co., Ltd., which aims to become a CNS (central nervous system) total solution company, in June 2020, aiming for early commercialization and early market penetration in the medical field.

concept encoderabout URL: https://lifescience.fronteo.com/concept-encoder/

"Concept Encoder (registered trademark: conceptencoder®, reading: concept encoder)" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

FRONTEOabout URL: https://www.fronteo.com/

FRONTEO Inc. has developed its own natural language analysis AI (artificial intelligence) engine "KIBIT".^®(Kibit) ”and“ Concept Encoder (registered trademark: concept encoder®, reading: concept encoder) ”are companies that support information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves evidence, investigates and analyzes electronic data necessary for international proceedings, and digital forensic investigations, and technologies such as an in-house developed data analysis platform To date, we have supported about 8 international proceedings.In addition, we are applying the unique AI-related technology cultivated in the legal business to areas such as life science and business intelligence, and have achieved results in drug discovery research support, diagnostic support, and work style reform. Listed on TSE Mothers on June 1, 2007.The capital is 6 thousand yen (as of March 26, 2,568,651).

Notices

This research and development is a medical device and system research and development project (medical support technology research and development project utilizing ICT) that realizes future medical care of the Japan Agency for Medical Research and Development (AMED) "Facial expression, voice, daily life activities" This was done with the support of "Development of a device that delivers an objective evaluation of mental symptoms in real time from the quantification of."